NCT03406507 - A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

March 25, 2020

Study Completion Date

August 25, 2022

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

BIOLOGICAL

Ravulizumab

Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.

Trial Locations (9)

Clinical Trial Site, Atlanta

Clinical Trial Site, Milwaukee

Clinical Trial Site, Paris

Clinical Trial Site, Utrecht

Clinical Trial Site, Oslo

Clinical Trial Site, Moscow

Clinical Trial Site, Saint Petersburg

Clinical Trial Site, Leeds

Clinical Trial Site, London